RxDoctor Payments Data

Pauline Aquino, MD

Family Medicine · Clio, MINPI 1356370407

Payments from drug & device makers

$3,672in general payments, 2019–2025

Across 110 payments — averaging $33.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$603
  • Bayer$426
  • AstraZeneca$391
  • Novo Nordisk$232
  • Merck$149
  • plus $391 from 8 others

What the payments were for

  • Food & beverage$3,672100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK16$1,480
AbbVie(2 entities)13$603
Bayer20$426
AstraZeneca(2 entities)19$391
Novo Nordisk12$232
Merck10$149
Exact Sciences6$114
Dexcom, Inc.2$71
Lilly USA, LLC4$61
Amgen3$56
Amarin Pharma, Inc.2$41
Astellas Pharma US Inc1$18
Otsuka America Pharmaceutical, Inc.1$18
Circassia Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,672 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$32,617
Medicare patients
79
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$44,324
JardianceEmpagliflozin32$35,033
JanuviaSitagliptin Phosphate44$33,799
OzempicSemaglutide32$29,828
MounjaroTirzepatide11$16,454
InvokanaCanagliflozin16$13,199
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$5,680
Fenofibrate26$4,251
Atorvastatin Calcium219$3,922
Levothyroxine Sodium305$3,810
Lisinopril328$3,299
Sertraline Hcl151$2,476
Simvastatin242$2,380
Metformin Hcl243$2,377
Metoprolol Succinate120$2,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$149$33,79944 claims
Novo NordiskOzempic$232$29,82832 claims
Lilly USA, LLCMounjaro$61$16,45411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Clio

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →